World Bank and Pfizer Announce Initiative to Help Improve Healthcare Delivery

Pfizer Inc.The World Bank and Pfizer Inc. announced they will collaborate to improve the healthcare infrastructure, specifically the supply chain, in developing countries, starting with Africa. The novel public-private collaboration will focus on enhanced use of Information and Communication Technologies' (ICT) transformative power to improve healthcare delivery. The project demonstrates both Pfizer's and the World Bank's commitment to improving healthcare delivery by creating a funding mechanism to expedite the identification of gaps in Africa's healthcare infrastructure and ultimately aid in the implementation of ICT solutions.

The effort will be part of the World Bank's new eTransform Initiative, which was formally launched at a World Bank Spring Meeting side event attended by developing country ministers of finance and communications. The eTransform Initiative aims to convene public and private sector stakeholders to promote government transformation through the use of innovative ICTs. The goal is to use technology to increase government effectiveness and help governments in developing countries use their healthcare and other resources more efficiently.

About 270 million people in Africa lack regular access to even the most essential medicines.(1) According to the World Health Organization (WHO), among the biggest obstacles to improved health outcomes are inadequate health delivery and financing mechanisms that place the heaviest burden on the poor and sick, who are the least able to pay.

"We recognize the importance of improving healthcare infrastructure in developing countries so more patients can have access to life-saving medicines," said Jean-Michel Halfon, president and general manager of Pfizer's Emerging Markets Business Unit. "This collaboration is the most recent example of Pfizer's Global Access strategy to improve healthcare access for low-income populations in emerging markets through non-traditional approaches that will contribute towards the development of commercially viable, sustainable delivery models."

The eTransform Initiative helps access global expertise through peer-to-peer networks of industry innovators and country leaders, and through a knowledge bank. It also establishes a mechanism to fast-track promising projects by funding their initial design. Under the eTransform Initiative, the World Bank and Pfizer will work together on knowledge-sharing initiatives. They will also work to set up a trust fund to finance innovative, ICT-based solutions to healthcare in developing countries.

The funding mechanism, or Healthcare Project Development Facility (HPDF), will be one of several sector-specific project development facilities within the eTransform Initiative. The HPDF entails that countries submit grant requests to support a competitively-bid feasibility study. Study outcomes serve as the basis for proposed solutions and, if accepted by the country and eligible for World Bank funding, the solution will be implemented on a country level.

The collaboration will focus on Africa in the initial phase. Africa is the world's fastest growing cellular market, with about 400 million mobile phones in use.(2) "With billions of people in the developing world having access to reliable technology, such as mobile communications, there is a tremendous opportunity to use technology to radically improve healthcare delivery," said Mohsen Khalil, director of the World Bank's Global Information and Communication Technologies Department. "Through public-private collaborations, which bring together global expertise, appropriate technologies, efficient processes, and necessary financial resources, the potential of health and technology can be fully realized."

The collaboration will focus on supporting the eTransform Initiative through studies or pilots that improve healthcare infrastructure and sharing global knowledge about technology in developing countries, including the use of mobile applications.

"We understand that to truly make a difference in the lives of low-income people in emerging markets, we first need research-based evidence to identify and better understand the existing capabilities and needs of a country to improve healthcare access for its people," said Ponni Subbiah, vice president, Pfizer Global Access.

about The World Bank
The World Bank is a multilateral development institution and one of the world's largest sources of financial and technical assistance to developing countries around the world. Comprised of 185 member governments, its primary focus is to help the world’s poorest people and the poorest countries. The World Bank uses its financial resources, its staff, and extensive experience to help developing countries reduce poverty, increase economic growth, and improve their quality of life. The World Bank is partnering with the ICT industry to leverage technology as an enabler in the context of the ICT Skills Development Initiative and the eTransform Initiative.

Pfizer Inc: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

1. BMJ 2005; 331:709-10.
2. "Africa: 448 million mobile network subscribers." Africa News. February 11, 2010.

Most Popular Now

How SARS-CoV-2 mutates to escape antibody binding

In a recurring pattern of evolution, SARS-CoV-2 evades immune responses by selectively deleting small bits of its genetic sequence, according to new research from the Uni...

Anticancer drug may improve outcome for severe COV…

Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China ...

One dose of COVID-19 vaccine provokes strong immun…

Although clinical trial data are encouraging, real-world evidence with regard to the COVID-19 vaccine remains scarce. In particular, response to the vaccine among those p...

Pfizer and BioNTech commence global clinical trial…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in a global Phase 2/3 study to further evaluate the saf...

Johnson & Johnson announces submission of appl…

Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen Biotech, Inc., has submitted an application to the U.S. Food and Drug Administration (FDA) requesting E...

Could a nasal spray prevent coronavirus transmissi…

A nasal antiviral created by researchers at Columbia University Vagelos College of Physicians and Surgeons blocked transmission of SARS-CoV-2 in ferrets, suggesting the n...

European Commission purchases additional 150 milli…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission purchased an...

GSK and Vir Biotechnology expand coronavirus colla…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) have signed a binding agreement to expand their existing collaboration to include the resear...

Neandertal gene variants both increase and decreas…

Last year, researchers at Karolinska Institutet in Sweden and the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany showed that a major genetic risk ...

CureVac initiates rolling submission with European…

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today annou...

Pfizer and BioNTech publish data from in vitro stu…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication in Nature Medicine of data from in vitro studies that demonstrate that sera from in...

Sinovac receives conditional marketing authorizati…

Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced that the China National Medical Produ...